North China Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
North China Pharmaceutical Co Ltd cash flow reinvestment rate. North China Pharmaceutical Co Ltd (600812) has a Cash Flow Reinvestment Rate of 0.85x as of September 2025, reinvesting CN¥144.38 Million (capex CN¥144.38 Million ) from operating cash flow of CN¥170.24 Million. See 600812 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of North China Pharmaceutical Co Ltd (2000–2025)
Cash flow reinvestment rate of North China Pharmaceutical Co Ltd from 2000 to 2025. Historical reinvestment intensity for North China Pharmaceutical Co Ltd across 22 annual periods. Explore North China Pharmaceutical Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
North China Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2000–2025)
North China Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2000 to 2025. Year-by-year capital reinvestment analysis for North China Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 600812 operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | CN¥781.54 Million | CN¥1.18 Billion | CN¥542.01 Million | ▼ -44.0% |
| 2024 | 1.19x | CN¥1.46 Billion | CN¥1.23 Billion | CN¥784.22 Million | ▼ -19.3% |
| 2023 | 1.47x | CN¥1.50 Billion | CN¥1.02 Billion | CN¥623.04 Million | ▲ +167.5% |
| 2022 | 0.55x | CN¥551.58 Million | CN¥1.00 Billion | CN¥549.58 Million | ▼ -26.8% |
| 2021 | 0.75x | CN¥787.50 Million | CN¥1.05 Billion | CN¥547.50 Million | ▼ -44.1% |
| 2020 | 1.34x | CN¥1.01 Billion | CN¥752.15 Million | CN¥1.01 Billion | ▲ +51.7% |
| 2019 | 0.88x | CN¥648.46 Million | CN¥732.97 Million | CN¥645.97 Million | ▲ +34.6% |
| 2018 | 0.66x | CN¥509.13 Million | CN¥774.33 Million | CN¥506.64 Million | ▼ -68.5% |
| 2017 | 2.09x | CN¥599.69 Million | CN¥287.25 Million | CN¥399.69 Million | ▼ -55.0% |
| 2015 | 4.64x | CN¥567.81 Million | CN¥122.50 Million | CN¥367.81 Million | ▲ +62.5% |
| 2014 | 2.85x | CN¥258.30 Million | CN¥90.56 Million | CN¥258.30 Million | ▼ -42.9% |
| 2011 | 4.99x | CN¥1.14 Billion | CN¥227.60 Million | CN¥1.14 Billion | ▲ +1279.5% |
| 2009 | 0.36x | CN¥366.10 Million | CN¥1.01 Billion | CN¥366.10 Million | ▲ +184.8% |
| 2008 | 0.13x | CN¥138.00 Million | CN¥1.09 Billion | CN¥138.00 Million | ▼ -14.1% |
| 2007 | 0.15x | CN¥98.27 Million | CN¥664.37 Million | CN¥98.27 Million | ▲ +70.8% |
| 2006 | 0.09x | CN¥51.72 Million | CN¥597.12 Million | CN¥51.72 Million | ▼ -89.5% |
| 2005 | 0.82x | CN¥184.67 Million | CN¥224.17 Million | CN¥184.67 Million | ▼ -26.6% |
| 2004 | 1.12x | CN¥348.50 Million | CN¥310.39 Million | CN¥348.50 Million | ▲ +47.2% |
| 2003 | 0.76x | CN¥442.77 Million | CN¥580.32 Million | CN¥442.77 Million | ▲ +150.8% |
| 2002 | 0.30x | CN¥224.68 Million | CN¥738.50 Million | CN¥224.68 Million | ▼ -41.7% |
| 2001 | 0.52x | CN¥191.79 Million | CN¥367.28 Million | CN¥191.79 Million | ▼ -28.5% |
| 2000 | 0.73x | CN¥97.52 Million | CN¥133.49 Million | CN¥97.52 Million | — |